by Fred Dumais | Feb 2, 2024 | News Release
Original commercialization and supply agreement amended following global divestment of XIIDRA® SIMBRINZA® remains under Valeo Pharma exclusive promotion and distribution Proceeds from reimbursement to be used for debt reduction purposes Sagard credit facility amended...
by Fred Dumais | Jan 29, 2024 | News Release
Record revenues of $54 million for fiscal 2023, up 94% over 2022 Revenues of $13.1 million for Q4-23, up 4% over Q4-22 Record annual adjusted gross profit of $16.9 million for 2023, compared to $9.4 million for 2022, up...
by Fred Dumais | Jan 22, 2024 | News Release
MONTREAL, QUEBEC , January 22, 2024 – Valeo Pharma Inc. (TSX:VPH, OTCQB: VPHIF, FSE:VP2) (“Valeo” or the “Company”), a Canadian pharmaceutical company, announced today that it will report its financial results and highlights for the fourth quarter and year ended...
by Fred Dumais | Nov 20, 2023 | News Release
Costs reduction initiatives and organizational realignment expected to generate annual savings exceeding $2 million. MONTREAL, QUEBEC, November 20, 2023 – Valeo Pharma Inc. (TSX: VPH, OTCQB: VPHIF, FSE: VP2) (“Valeo” or the “Company”), a Canadian pharmaceutical...
by Fred Dumais | Nov 7, 2023 | News Release
MONTREAL, QUEBEC, November 7, 2023 – Valeo Pharma Inc. (TSX: VPH, OTCQB: VPHIF, FSE: VP2) (“Valeo” or the “Company”), a Canadian pharmaceutical company, today announced that Mr. Richard Lajoie has joined the Company’s Board of Directors and that Ms. Maureen C....
by Fred Dumais | Oct 4, 2023 | News Release
MONTREAL, QUEBEC , October 4, 2023 – Valeo Pharma Inc. (TSX:VPH, OTCQB: VPHIF, FSE:VP2) (“Valeo” or the “Company”), a Canadian pharmaceutical company, is pleased to announce it placed No. 151 on the 2023 Report on Business ranking of Canada’s Top Growing...